This area of our website is for healthcare professionals only

Please click below to declare your professional status:

YES, I am a healthcare professional  NO, I am not a healthcare professional

Conference Programme 2022

The HEART UK 2022 conference programme will feature

Register here

View programme schedule


CPD pending

      BDA endorsement applies only to the educational content of the learning activity.

- 7 plenaries 
- Clinical Lipidology Live interactive session
 -10 oral communication presentations representing Medical & Scientific and Primary & Healthcare
- Poster sessions
- 4 Supported symposia
- Engaging industry exhibition 
- Welcome reception (catch up with old friends and meet new connections)
- Conference dinner

** New for 2022 **Meet the Expert Taster sessions | Thursday 7 July

Join our expert(s) over lunch in an information setting for 2 x 20 minute taster sessions to learn about and discuss:

  • Pill Swallowing (discussing the barriers to adherence with lipid-lowering medicines)
  • Careers in Lipidology (discussing Nurses career paths and credentialling for nurses)

View programme schedule

The organisers reserve the right to change the programme at any time.


  • Celebrating 20 years since the BHA/FHA merger
  • Pharmacists view and new treatments
  • CVD Risk and gender- reassignment
  • Statin myopathy and myositis
  • Cardiac CT interpretation by lipidologists
  • Lp(a) scientific update / prevalence
  • State of the nation - UK view on Lp(a)
  • Fat versus carbohydrates in the management of blood lipids - the controversy
  • Clinical Lipidology Live - patient case studies and discussion

View programme

Disclaimer statement:
The conference is sponsored by various organisations.  These organisations have had no input into the development of the conference programme, or influenced the choice of speakers.
This excludes the sponsored symposia sessions where the programme is developed and speakers identified by the sponsor. Sponsoring organisations will  not be contributing in any way to the organisation and running of any social activities around the conference period.


Dr Jaimini CEGLA

Consultant in chemical pathology and metabolic medicine

Imperial College Healthcare NHS Trust



Dr Jai Cegla has a specialist interest in lipidology and cardiovascular risk and splits her time between clinical, laboratory and academic research roles. In her clinical role she looks after the Hammersmith Hospital Lipid Service, a one-stop centre for the genetic diagnosis and management of lipid disorders.


Her current research focuses on cardiovascular risk including clinical trials of novel therapeutic agents.


Dr Cegla is a member of the Medical, Scientific and Research Committee of HEART UK, the cholesterol charity. She also contributes to the NHS England Clinical Advisory Group for Lipids.


PhD Candidate

University of Surrey



Alan is currently a PhD candidate in nutrition at the University of Surrey, having completed his Masters degree in nutrition science at the same institution. Alan is the founder of Alinea Nutrition, an online education hub dedicated to providing impartial, science-based nutrition analysis. Alan is also Research Communication Officer for Sigma Nutrition, creating educational resources for nutrition science. Originally a lawyer by background in Dublin, Ireland, Alan spent a decade practicing as a barrister before moving into science.





HighParks Medical Practice, Cliffe Woods, Kent


GP Governing Body Member | Kent & Medway CCG

Clinical Lead | CVD Prevent Audit 

Chair | HEART UK  

Professor Bruce GRIFFIN

Professor of Nutritional Metabolism, and Research Section Lead in Metabolic Medicine, Food & Macronutrients

Department of Nutritional Sciences

University of Surrey in Guildford


He is Editor-in-Chief of the European Journal of Nutrition, Council Member for Academia for the British Nutrition Society, and a Registered Nutritionist through affiliation with the Association for Nutrition. After a BSc in Medical Laboratory Science (Portsmouth, 1984), he undertook a PhD (Effects of exercise and diet on plasma lipoproteins, Aberdeen, 1988), followed by post-doctoral training in pathological biochemistry at Glasgow Royal Infirmary (1988-94). At the University of Surrey (1994-to date), he has researched and taught undergraduate and postgraduates in human nutrition & dietetics, food science, nutritional medicine, and clinical biochemistry. He has published extensively on the effects of dietary macronutrients and lifestyle factors on human health and cardiovascular diseases, with focus on the impact of blood lipids and lipoproteins.



Consultant | Rheumatology, Autoimmune Connective Tissue Disease & Vasculitis

Rheumatology Speciality Lead

Southmead Hospital

North Bristol NHS Trust


Dr Gunawardena runs the North Bristol Connective Tissue Disease and Vasculitis clinic. He runs a tertiary level service with three dedicated CTD Vasculitis clinics per week (seeing GP and secondary care referrals), including a rapid access clinic pathway for urgent patients. With the Bristol Interstitial Lung Disease Team, he runs CTD-ILD service.


He is Clinical Lead for the Medical Day Care Unit.


Dr Gunawardena has a clinical and academic interest in all aspects of Autoimmune CTD and vasculitis. His PhD was on the identification of novel autoantibody markers in inflammatory muscle and lung disease. He has published widely on immunological aspects of CTD as biomarkers of disease. He is currently involved in the following registry studies: European Scleroderma Observational Study, Scleroderma Digital Ulcer Register, UK MyoNet and UK ILD Genetics and Antibody studies. He was the scientific advisor to the UK Juvenile Myositis Research Group (2012-2015). He is on the steering committee of the UK Myositis Network. He is also a member of the UK Scleroderma Study Group. Dr Gunawardena advises a number of UK CTD patient support groups.


Clinical Lecturer

Queen’s University Belfast


Paul Hamilton is also an Honorary Consultant Chemical Pathologist at Belfast Health and Social Care Trust. He has an interest in cardiovascular and fracture risk, as well as medical education. Paul works in a busy general lipid clinic and also runs a separate clinic for patients with Familial Hypercholesterolaemia. His MD thesis was in the field of refining cardiovascular risk and he has published several articles in this area.



Consultant Chemical Pathologist 

Department of Clinical Biochemistry

Royal Infirmary of Edinburgh


Sara Jenks qualified from Warwick Medical School in 2007. After completing foundation training in the West Midlands she moved to Edinburgh, Scotland where she went on to complete her core medical training and specialty training in chemical pathology and metabolic medicine at the Royal Infirmary of Edinburgh.   


Her clinical interests include lipidology and inherited metabolic disease.  She works at the Royal Infirmary of Edinburgh lipid service which provides the full range of investigation and treatment for patients with lipid disorders.  


Dr Jenks chairs multiple committees at local and national level including the Lothian Primary care laboratory interface group and the Scottish Clinical Biochemistry network innovation group. She is also a member of the Scottish Lipid Forum. 



Consultant Pharmacist in Cardiology & Cardiovascular Research│Leeds Teaching Hospitals NHS Trust 

Associate Professor │University of Leeds 

National Clinical Champion for PCSK9i & Lipid Management│NHS England  

Heart Failure Quality Standards Committee member│NICE

Science Committee Member│European Soceity of Cardiology, ACNAP 

Co-Chair of Cardiovascular Group│UK Clinical Pharmacy Association  






PhD, MPharm, PGDip, MRPharmS

L/SL Clinical Pharmacy and Therapeutics

Liverpool John Moores University, Liverpool


Dr Alice McCloskey is a registered pharmacist working primarily in academia who keeps in touch with practice through regular locum days in community and hospital pharmacy. Frequent patient contact ensures that Dr McCloskey’s research is both informed by and contributes to better patient care. A Queen’s University Belfast MPharm and PhD graduate, Dr McCloskey completed an industry linked post-doctoral fellowship between the Royal College of Surgeons in Ireland, Dublin and nebulizer company aerogen, Galway. She has worked as a full-time academic since 2018. Dr McCloskey’s research areas span the breadth of pharmacy science to clinical practice, with specific interests being peptides, paediatrics and pills.


At this year’s HEART UK conference she will share recent work with Newcastle and Liverpool Children’s hospitals around pill swallowing that is as applicable for adult cardiology patients as they are for children.

Dr Devaki NAIR

Consultant Chemical Pathologist  and Clinical Lead for Clinical biochemistry Royal Free hospital and North Middlesex University Hospital

Clinical Lead for Lipids and CVD Prevention

Director SAS Centre for Cardiovascular Biomarkers, Training Programme Director for Chemical Pathology and Metabolic Medicine; Speciality Lead for Biochemistry HSL

Prof Frederick J RAAL

MBBCh, FRCP, FCP(SA), Cert Endo, MMED, PhD

Head, Division of Endocrinology & Metabolism
Director, Carbohydrate and Lipid Metabolism Research Unit Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa


Professor Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.


He has authored or co-authored over 300 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis.  He is on the Editorial Board of Atherosclerosis and is a Board member of the International Atherosclerosis Society.


Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). His Unit has one of the largest cohorts, if not the largest cohort, of homozygous FH patients in the world and has contributed and continues to contribute to the management of these patients. The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.

Dr Jonathan C. L. RODRIGUES

BSc(Hons), MBChB(Hons), MRCP, FRCR, FSCMR, PhD

Consultant Radiologist, Department of Radiology, Royal United Hospitals Bath NHS Foundation Trust

Honorary Senior Lecturer, Department of Health, University of Bath




Consultant Chemical Pathologist

St Richard’s Hospital, Chichester

Dr Yee-Ping TEOH

Consultant in Chemical Pathology and Metabolic Medicine

Clinical Lead for Services in Betsi Cadwaladr University Health Board

Betsi Cadwaladr University Health Board

Department of Clinical Biochemistry, Pathology Department,

Wrexham Maelor Hospital,

Wrexham, UK


Yee-Ping is originally from Malaysia and did her undergraduate medical training in Melbourne, Australia before continuing her postgraduate training in UK since 1997.


She was accepted to the West of Scotland Chemical Pathology and Metabolic Medicine Specialist Registrar training in Glasgow from 2002-2008 where her interest in dyslipidaemia treatment started.


Yee-Ping was appointed into her current post as Consultant Chemical Pathologist in Wrexham since 2008. As there were no Lipid clinics in North Wales at that time, she started the first Lipid clinic in Nov 2008 and there is now a lipid clinic in each of the 3 hospitals in BCUHB. Together with her Familial Hypercholesterolaemia (FH) nurse specialist Rob Gingell and two other consultant colleagues, they have been running the All Wales Familial Hypercholesterolaemia screening programme since 2010 and have a large database of FH patients under their care. They run a mixture of face-to-face clinics and also virtual clinics to help both primary and secondary care consultants managed difficult to treat dyslipidaemic patients in the region.


Yee-Ping is also passionate about clinical research and have been involved with some of the current Phase III cardiovascular outcome trials for lipid lowering agents.




Prof Sotirios (Sam) TSIMIKAS


Medicine and Director of Vascular Medicine

University of California San Diego School of Medicine, San Diego, USA


Dr. Tsimikas is Professor of Medicine and the Director of Vascular Medicine at the University of California San Diego School of Medicine. His education and training included obtaining his MD degree from the University of Massachusetts Medical School, Internal Medicine training at the University of Massachusetts Medical Center, and separate fellowships in Cardiovascular Medicine, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego (UCSD( Medical Center. Dr. Tsimikas is the Founding Director of the Vascular Medicine Program withing the Cardiovascular Medicine Division, which encompasses treating patients in the continuum of high-risk primary prevention to endovascular intervention. In 2014, he established the world’s first dedicated “Lp(a) Clinic”. Dr. Tsimikas’ research interests are translational in scope and focus on two major areas: 1-“biotheranostics”- biomarkers, molecular imaging and therapeutics targeted to oxidation-specific epitopes, and 2- Lp(a) pathophysiology and therapeutics. He has published in all of the major medical journals, including NEJM, Lancet, Nature, Cell and has over 280 original manuscripts, review articles and book chapters. He currently has a dual appointment at University of California San Diego Medical School and as Senior Vice President of Global Cardiovascular Development at Ionis Pharmaceuticals, Carlsbad, CA. He is co-inventor of 13 issued patents, and co-founder of Oxitope, Inc, Kleanthi Diagnostics and Covicept Inc.